A review of the clinical efficacy of FDA-approved antibodyâdrug conjugates in human cancers.
Mol Cancer
; 23(1): 62, 2024 03 23.
Article
em En
| MEDLINE
| ID: mdl-38519953
ABSTRACT
While strategies such as chemotherapy and immunotherapy have become the first-line standard therapies for patients with advanced or metastatic cancer, acquired resistance is still inevitable in most cases. The introduction of antibodyâdrug conjugates (ADCs) provides a novel alternative. ADCs are a new class of anticancer drugs comprising the coupling of antitumor mAbs with cytotoxic drugs. Compared with chemotherapeutic drugs, ADCs have the advantages of good tolerance, accurate target recognition, and small effects on noncancerous cells. ADCs occupy an increasingly important position in the therapeutic field. Currently, there are 13 Food and Drug Administration (FDA)âapproved ADCs and more than 100 ADC drugs at different stages of clinical trials. This review briefly describes the efficacy and safety of FDA-approved ADCs, and discusses the related problems and challenges to provide a reference for clinical work.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Imunoconjugados
/
Neoplasias
/
Antineoplásicos
Limite:
Humans
País/Região como assunto:
America do norte
Idioma:
En
Revista:
Mol Cancer
Ano de publicação:
2024
Tipo de documento:
Article